You may be aware that last month the first oral GLP-1 was approved by the FDA for Type 2 diabetes! It is called Rybelsus (semaglutide). Here is the press release with more information: https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-glp-1-treatment-type-2-diabetes
This is exciting, as for many patients with diabetes, a pill feels less invasive than an injection. There are some stipulations with taking this drug, such as that it should be taken at least 30 minutes before the first food, beverage or other oral medication of the day, with no more than 4 ounces of plain water. These will be important education points to hit on for patients that we see on this drug in the future.
You can sign up on Novo Nordisk’s website to get updates for when Rybelsus will be available in your area. The diabetes medication landscape is fast-moving and ever changing!
Remember about the AADE member benefit DANA for up to date information on all diabetes technology as well!